Abstract Details

Title Oligoclonal band number as a predictor of multiple sclerosis disease course

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-014

Objective

To address whether the number of oligoclonal bands (OCBs) is predictive of disease course activity and progression in multiple sclerosis (MS).

Background While many studies have examined the presence or absence of OCBs with regard to prognosis in MS, there have been no large studies investigating relationships between the number of OCBs across several disease metrics.

Design/Methods In this retrospective study, data was gathered from Penn Data Store for patients who underwent OCB testing from January 2011 to January 2015. Further selection criteria included a diagnosis of relapsingremitting MS, adherence to a disease-modifying therapy (DMT) initiated within three months of diagnosis, and two years of follow-up clinical visits and imaging. Outcome measures were clinical relapses (# steroid prescriptions), radiographic relapses (# new lesions on MRI), clinical progression (categorized by degree ambulatory assist), and radiographic progression (>1% brain volume loss) at two-year follow-up.

Results Of 2277 patients screened, 204 patients had OCB testing and MS. With 128 meeting inclusion criteria, 118 patients (92%) had positive OCBs. With a range of 0-23 bands, the cohort was divided into two groups: OCBs <10 (62) and ≥10 (66). After two years, patients with ≥10 OCBs had significantly higher annualized clinical and radiographic relapse rates. Regarding progression, use of a new assistive device and accelerated brain volume loss (>1%) was significantly more likely for patients with ≥10 OCBs. In a subgroup controlling for the most common DMT (glatiramer acetate), these findings were upheld.

Conclusions This study shows significantly greater relapses and progression, both clinical and radiographic, for patients with high levels (≥10) of OCBs early in the MS disease course. As OCBs will have greater diagnostic weight going forward, the quantity may be important in guiding selection of DMTs.

Authors/Disclosures
Christopher Perrone, MD (University of Pennsylvania, Department of Neurology) PRESENTER	Dr. Perrone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Clyde E. Markowitz, MD (Hospital of the Univ of Pennsylvania)	No disclosure on file
Joseph R. Berger, MD, FAAN	Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb/Celgene. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle Pharma. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dice Therapeutics. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Gilead. Dr. Berger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck/. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Morphic. Dr. Berger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MAPI. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ExcisionBio. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Population Bio. Dr. Berger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Berger has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Assorted .

��ɫ��

��ɫ��